Movement Alert｜GlaxoSmithKline PLC Rises 4.07% in Regular Trading, Lung Cancer Drug Jideytro Achieves 94% Response Rate in First-Line Trial

Market Focus09-14 21:38

On September 14, GlaxoSmithKline PLC rose 4.07% in regular trading, trading at $49.97/share, with turnover of $24.3989 million.

On the news front, the company disclosed clinical trial data for its lung cancer drug zidesamtinib (branded as Jideytro) in first-line treatment of advanced ROS1-positive non-small cell lung cancer, reporting a 94% objective response rate among patients who had not received prior targeted therapy. Notably, all participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. Treatment-related adverse events led to dose reductions in only 11% of patients and discontinuations in just 1%. The company plans to submit an application to the FDA this year to expand the drug's approval for first-line use. Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer.

Additionally, GSK licensor Hansoh Pharmaceutical reported that its ADC drug Ris-Rez met the primary endpoint in a Phase III trial for relapsed small cell lung cancer, further boosting market confidence in GSK's oncology pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167934008?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167934008","market":"us","top_or_hot":-1,"title":"Movement Alert｜GlaxoSmithKline PLC Rises 4.07% in Regular Trading, Lung Cancer Drug Jideytro Achieves 94% Response Rate in First-Line Trial","media":"Market Focus","content":"<p><p>On September 14, GlaxoSmithKline PLC rose 4.07% in regular trading, trading at $49.97/share, with turnover of $24.3989 million.</p><p>On the news front, the company disclosed clinical trial data for its lung cancer drug zidesamtinib (branded as Jideytro) in first-line treatment of advanced ROS1-positive non-small cell lung cancer, reporting a 94% objective response rate among patients who had not received prior targeted therapy. Notably, all participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. Treatment-related adverse events led to dose reductions in only 11% of patients and discontinuations in just 1%. The company plans to submit an application to the FDA this year to expand the drug's approval for first-line use. Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer.</p><p>Additionally, GSK licensor Hansoh Pharmaceutical reported that its ADC drug Ris-Rez met the primary endpoint in a Phase III trial for relapsed small cell lung cancer, further boosting market confidence in GSK's oncology pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GlaxoSmithKline PLC Rises 4.07% in Regular Trading, Lung Cancer Drug Jideytro Achieves 94% Response Rate in First-Line Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GlaxoSmithKline PLC Rises 4.07% in Regular Trading, Lung Cancer Drug Jideytro Achieves 94% Response Rate in First-Line Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-14 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 14, GlaxoSmithKline PLC rose 4.07% in regular trading, trading at $49.97/share, with turnover of $24.3989 million.</p><p>On the news front, the company disclosed clinical trial data for its lung cancer drug zidesamtinib (branded as Jideytro) in first-line treatment of advanced ROS1-positive non-small cell lung cancer, reporting a 94% objective response rate among patients who had not received prior targeted therapy. Notably, all participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. Treatment-related adverse events led to dose reductions in only 11% of patients and discontinuations in just 1%. The company plans to submit an application to the FDA this year to expand the drug's approval for first-line use. Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer.</p><p>Additionally, GSK licensor Hansoh Pharmaceutical reported that its ADC drug Ris-Rez met the primary endpoint in a Phase III trial for relapsed small cell lung cancer, further boosting market confidence in GSK's oncology pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"","article_id":"1167934008","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167934008","pubTimestamp":1789393130,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 14, GlaxoSmithKline PLC rose 4.07% in regular trading, trading at $49.97/share, with turnover of $24.3989 million.On the news front, the company disclosed clinical trial data for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"动向提醒|葛兰素史克公司常规交易涨4.07%，肺癌药物Jideytro一线试验应答率达94%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1},"content_text":"On September 14, GlaxoSmithKline PLC rose 4.07% in regular trading, trading at $49.97/share, with turnover of $24.3989 million.On the news front, the company disclosed clinical trial data for its lung cancer drug zidesamtinib (branded as Jideytro) in first-line treatment of advanced ROS1-positive non-small cell lung cancer, reporting a 94% objective response rate among patients who had not received prior targeted therapy. Notably, all participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. Treatment-related adverse events led to dose reductions in only 11% of patients and discontinuations in just 1%. The company plans to submit an application to the FDA this year to expand the drug's approval for first-line use. Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer.Additionally, GSK licensor Hansoh Pharmaceutical reported that its ADC drug Ris-Rez met the primary endpoint in a Phase III trial for relapsed small cell lung cancer, further boosting market confidence in GSK's oncology pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167934008","isCrawlerRequest":true}